Jon Miller, White House Correspondent for CRTV, discusses the GOP tax bill, which could be voted on as early as Tuesday. The Republican Party secured the number of votes needed to pass the bill on Friday, when Senators Marco Rubio and Bob Corker jumped on board. Miller notes his surprise with Corker deciding to vote for the bill, given how bothered he was originally by the $1.4 trillion it would add to the deficit. We discuss how unfavorable the bill is polling with the American people. Miller adds that much of that is because he does not think the media is doing a good job of being honest about the bill. In addition to that, 45% of Americans don't actually pay taxes. Millers talks the overall good the bill will do for the economy and business-owners.

Share:
More In Business
17 Digital Asset Firms Launch CMIC, Committing to Safer Markets and Working with Regulators
Soildus Labs, a market compliance and surveillance technology provider for crypto firms, has spearheaded the launch of the Crypto Market Integrity Coalition, a pledge committing to a safe and sensibly-regulated crypto industry. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, discusses on Cheddar News' Closing Bell the biggest problems in the digital asset space that this new initiative plans to solve.
Stocks Close Mixed as Investors Process Earnings, Look Ahead to Thursday CPI
Stocks closed mixed Monday as a broader tech sell-off continued, leading the Nasdaq to close down 0.58%. Investors are keeping an eye on earnings, and also looking ahead to Thursday's CPI data, which will give an idea of how hot inflation could still be running. Steve Sosnick, Chief Strategist at Interactive Brokers, joins Closing Bell to discuss today's close, the Federal Reserve's plans to raise interest rates and taper asset purchasing, his 2022 market outlook, and more.
Chip Shortage Continues to Impact Automobile Production
The global chip shortage continues to weigh on the automotive industry. For example, Ford says it is suspending or cutting production at eight of its factories in North America through next week due to the shortage. Balu Balakrishnan, President and CEO of Power Integrations, joins Cheddar News' Closing Bell, where he elaborates on why the chip shortage has dragged into 2022.
Dan Ives: Apple is Likely 'Aggressively' Pursuing Peloton Takeover
Peloton has weathered a seemingly never-ending storm the past few months: PR blunders, sinking customer demand, and in recent weeks, reported cost-cutting and potential layoffs. Now, several companies are said to be in the mix as potential buyers: Amazon, Netflix, Disney, and Apple. How likely is it that one of these companies pursues a deal — and how likely is it that it will be Apple who buys Peloton? Dan Ives, Managing Director of Equity Research at Wedbush Securities, joins Closing Bell to discuss his thoughts about Apple pursuing a Peloton takeover,
Astra Scrubs NASA ELaNa 41 Space Launch, Sees Its Stock Fall
Astra aborted the launch for NASA ELaNa 41 Mission out of Cape Canaveral on Monday due to what was described as a minor issue, but the company's stock fell nearly 14 percent following the news. Jim Cantrell, CEO and co-founder of Phantom Space, which builds and launches spacecraft of its own, joined Cheddar to discuss the scrubbed mission. “The last thing you want is for this to go wrong, you're better to err on the side of safety expectations,” Cantrell explained, noting that the mission delay was a normal event.
TC BioPharm Goes Public, Looks to Future of Cancer, COVID-19 Cell Therapies
TC BioPharm, a biopharmaceutical company focused on developing cell therapy products targeting, went public on the Nasdaq in January. CEO Bryan Kobel joined Cheddar to talk about the company's IPO launch, its cancer-fighting therapeutics tech, and its potential for using its research to treat COVID-19. "The opportunity here for us is to really get safety data and covid and expand into other areas," Kobel said. "So from COVID, where we hope to treat patients, hopefully maybe the elderly population, populations that that really can't handle the antivirals because they're too hard in the system, well then we'll expand out into maybe severe influenza Ebola, other viral and viral infections where we think we can be helpful."
Load More